Genmab AS (GMAB)vsEli Lilly and Company (LLY)
GMAB
Genmab AS
$26.11
-2.54%
HEALTHCARE · Cap: $16.45B
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1652% more annual revenue ($65.18B vs $3.72B). LLY leads profitability with a 31.7% profit margin vs 25.9%. LLY appears more attractively valued with a PEG of 1.29. LLY earns a higher WallStSmart Score of 78/100 (B+).
GMAB
Buy54
out of 100
Grade: C-
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.4%
Fair Value
$58.29
Current Price
$26.11
$32.18 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.0%
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
GMAB profiles as a value stock while LLY is a growth play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.74 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 54/100), backed by strong 31.7% margins and 42.6% revenue growth. GMAB offers better value entry with a 48.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?